Navigation Links
ImaRx Schedules Release of First Quarter 2008 Financial Results
Date:5/7/2008

Live Webcast and Conference Call Scheduled for Tuesday, May 13th at 5 PM ET

TUCSON, Ariz., May 7 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX) today announced that the Company will host a live webcast and conference call on Tuesday, May 13, 2008, at 5:00 p.m. ET to discuss first quarter 2008 financial results.

The live webcast can be accessed through ImaRx's corporate website at http://www.imarx.com and will be archived on the website for 14 days following the event.

Interested parties may access the conference call by dialing (877) 407-4018 in the U.S. and Canada or (201) 689-8471 internationally. A telephonic replay will be available through May 20, 2008 by dialing (877) 660-6853 in the U.S. and Canada or (201) 612-7415 internationally (Account Number 3055 and Conference ID 284385).

About ImaRx Therapeutics

ImaRx Therapeutics is a biopharmaceutical company developing and commercializing therapies for vascular disorders. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology. The Company's commercialization efforts are currently focused on its product, urokinase, for the treatment of acute massive pulmonary embolism.

Contacts:

The Ruth Group (Investors/Media)

Sara Ephraim/Jason Rando

646-536-7002 or 7025

sephraim@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. ImaRx to Report Corporate Updates and 4Q07 Financial Results
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
5. ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQs Minimum Bid Price Requirement
6. ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
7. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
8. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
9. LifeCell Corporation Schedules Third Quarter 2007 Financial Results Conference Call; October 25, 2007 at 10:00 A.M. Eastern
10. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
11. WorldHeart Schedules Teleconference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... (PRWEB) August 22, 2014 The AMA ... and its members in Alaska that Alaska Governor Sean ... Resolution 15, further defining public use of Unmanned Aircraft ... Task Force. House Bill 255states that it is, “An ... images captured by an unmanned aircraft system.” It defines ...
(Date:8/22/2014)... Toronto, Canada (PRWEB) August 22, 2014 ... traits in model organisms can be accelerated by ... design and manufacturing technologies, the custom SeqCap EZ ... such research. , Mr. Watson will additionally present ... seen with commercially available human and mouse exome ...
(Date:8/21/2014)... 2014  BioSpecifics Technologies Corp. (NASDAQ: ... class collagenase-based products marketed as XIAFLEX ® ... and XIAPEX ® in the EU, today ... double-blind Phase 2a study of CCH for the ... The results showed that all three doses of ...
(Date:8/21/2014)... at the Institute for Molecular Medicine Finland (FIMM), ... developed a novel "man and machine" decision support ... aid was described in PLOS One ... based on computer vision algorithms similar to those ... of only the diagnostically most relevant areas. Tablet ...
Breaking Biology Technology:State of Alaska Signs Unmanned Aircraft Systems Bill 2Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5A novel 'man and machine' decision support system makes malaria diagnostics more effective 2
... stents after opening clogged arteries has led a team of ... in Milwaukee to suggest that stents designed with thinner ... generation of stents. Their findings are published in the July ... , ,One of the most common methods for treating heart ...
... medical profession, one of the greatest obstacles in taking ... that naturally accompanies treatment. Patient histories and care instructions ... if multiple hospitals are involved, more levels of complication ... all this information seems like a Holy Grail, a ...
... of technological innovation sometimes starts out-of-control wildfires of politics, ... IT shop. If youre lucky, youve got some folks ... rapidly shifted from their regular duties to handle the ... reputations are more common results. If youre particularly unlucky, ...
Cached Biology Technology:Medical College discovery leads to new stents 2Human factors and IT: Designing for patient safety 2Human factors and IT: Designing for patient safety 3IT wildfires 2IT wildfires 3
(Date:8/21/2014)... including researchers from the University of Georgia recently published the ... journal Science . Their discovery paves the way for ... farming and industry. , Canola is grown across much ... is increasingly cultivated in Georgia. Canola oil used for cooking ... and rich supply of omega-3 fatty acids, but the plant ...
(Date:8/21/2014)... -- Nxt-ID, Inc. (OTCQB: NXTD), a biometric authentication company ... that its shares of common stock and the warrants ... proposed underwritten public offering of common stock and warrants ... Market, subject to closing of its proposed underwritten public ... trade under the symbol "NXTD" and "NXTDW," respectively. ...
(Date:8/21/2014)... and other itchy, flaky maladies in humans has now ... reefs and the extreme environments of arctic soils and ... journal PLOS Pathogens considers the diversity, ecology, ... Malassezia in light of new insights gained from ... University of Hawai,i at Mānoa scientist Anthony Amend discovered ...
Breaking Biology News(10 mins):Canola genome sequence reveals evolutionary 'love triangle' 2Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2
... Mathematical models have become invaluable decision-making tools for ... Kingdom's foot-and-mouth epidemic of 2001, models can be ... underlying characteristics of an infection and they can ... however, such models make implicit assumptions that may ...
... pandas in California or kangaroos in Argentina. , For David ... a professor of integrative biology at the University of California, ... of a type of salamander that comprises the majority of ... and rare outside the Americas. , "I've discovered and named ...
... have solved the structure of a crucial human immune ... three. In an upcoming issue of the journal Science, ... composed of 23 leucine-rich repeats (LRRs). , The structure ... before, an essential step toward fully understanding the critical ...
Cached Biology News:Understanding biases in epidemic models important when making public health predictions 2Discovery of an American salamander where it shouldn't be: Korea 2Discovery of an American salamander where it shouldn't be: Korea 3Discovery of an American salamander where it shouldn't be: Korea 4Scripps research scientists solve structure of a critical innate immune system protein 2Scripps research scientists solve structure of a critical innate immune system protein 3Scripps research scientists solve structure of a critical innate immune system protein 4
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
... and IHC Protocol Development ,Antibody Titer ... in Animal or Human Cells and ... and Tissues ,Peroxidase, Alkaline Phosphatase, Immunogold, ... Electron Microscopy ,Protein Localization in Transgenic ...
Biology Products: